Published in Vaccine Weekly, September 6th, 1999
PRI conducted a Phase II, placebo-controlled, randomized study of healthy volunteers infected with a susceptible strain of Influenza A and has provided preliminary results to BioCryst. The primary efficacy endpoint was the reduction in viral titers in infected subjects. Preliminary results showed a statistically significant result for the primary endpoint and evaluation of safety showed that the drug was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly